EMHLondonUK, I am sure that the FDA has all of the raw numbers and datasets from all of the ECA clinical trials. I believe that NWBio can and will make any adjustments to their DCVax-L clinical trial results analysis required or recommended by the FDA.
Even so, the blinded and blended OS for the ITT population in the DCVax-L trial was 23.1 months. In my opinion, the unblinded and unblended OS will be 27 to 30 months. Regardless of any adjustments, the DCVax-L results will be “ground-breaking” and IMO will change the SOC for ndGBM and rGBM.
Market Data 
Markets 
AI
